Additional Positive Efficacy Data with BI-1808 monotherapy from Ph 2a anti-TNFR2 program Announced
“We are thrilled by the observation of these partial responses in the CTCL cohort, which, together with the previously reported data, support the potential of BI-1808 to become a new class of immunomodulatory treatment option for patients with different kinds of cancers,” said Martin Welschof, Chief Executive Officer at BioInvent. “CTCL is an important indication where there is a high unmet need for new safe and effective solutions for patients, and we are now evaluating the next possible steps to accelerate the development of BI-1808 in this disease. We look forward to the emerging data from this trial from the CTCL cohorts as well as the ovarian cancer, and additional cohorts”.
Share:
More News
“The positive outcome of our pre-IND interactions with the FDA reinforces the development pathway for MaaT034 and supports its continued advancement toward the clinic. It also represents an important step in MaaT Pharma’s expansion into immuno-oncology, highlighting the broader potential of our first in class co-cultivated microbiome donor-independent platform across
“Patients with metastatic RAS G12D non-squamous NSCLC, occurring in approximately 4% of cases, represent an underserved population, with no approved targeted treatment options. Initial clinical data evaluating zoldonrasib in combination with standard of care pembrolizumab and platinum doublet chemotherapy in patients with previously untreated metastatic RAS G12D non-squamous NSCLC showed
“At Georgiamune, we are focused on uncovering novel mechanisms that control immune-cell function and translating that biology into first-in-class medicines across autoimmune disease and oncology,” said Samir N. Khleif, M.D., Founder and Chief Executive Officer of Georgiamune. “GIM-621 is one of multiple programs to emerge from that work, alongside three
“Our team’s outstanding execution has enabled us to rapidly advance three programs into the clinic in 2026 and make significant progress in developing next-generation IO, ADC and combination therapies. Together with our partner, Kelun-Biotech, we have achieved seven IND clearances to date, and by mid-2027, we expect more than 2,000